Prothena Corporation PLC
NASDAQ:PRTA
Intrinsic Value
Prothena Corp. Plc is a clinical-stage neuroscience company. [ Read More ]
The intrinsic value of one
PRTA
stock under the Base Case scenario is
53.69
USD.
Compared to the current market price of 20.56 USD,
Prothena Corporation PLC
is
Undervalued by 62%.
PRTA's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
PRTA or that its price is influenced by factors unrelated to fundamentals.
Prothena Corporation PLC's market capitalization is 1.1B USD.
PRTA stock price is 20.56 USD.
PRTA stock price (20.56 USD) is 62% less than its Intrinsic Value (53.69 USD).
PRTA. Open DCF Valuation
PRTA stock price (20.56 USD) is 62% less than its Relative Value (53.69 USD). Open Relative Valuation
PRTA has upside potential of 231% compared to the average analyst price target.
Open Wall St Estimates
PRTA's Revenue has grown by an exceptional 70% over the past 12 months.
PRTA's ROE (Return on Equity) has significantly increased in the last 3 years from -51% to -25%, and is approaching profitability.
PRTA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -328% to -387%, and is approaching profitability.
PRTA's Revenue is forecast to grow at a rate of 31% per year over the next 3 years.
PRTA has negative Operating Income for the last twelve months.
PRTA has negative Net Income for the last twelve months.
PRTA's ROE (Return on Equity) for the past 12 months is negative and is equal to -25%.
PRTA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -387%.
PRTA has negative Free Cash Flow for the last twelve months.
PRTA's Revenue has been growing by an exceptional 367% per year for the last 3 years.
PRTA has negative three-year average ROE (Return on Equity): -17%. The company is not efficient at transforming stockholders' equity into net income.
PRTA has negative three-year average ROIC (Return on Invested Capital): -177%. The company is not efficient at using invested capital to generate operating income.
PRTA's short-term assets (639m USD) exceed its short-term liabilties (57m USD).
PRTA's long-term assets (696m USD) exceed its long-term liabilties (135m USD).
PRTA's D/E (Debt to Equity) is very low and is equal to 0.
PRTA's Altman Z-Score is very high and is equal to 5.86.
Valuation Backtest
Prothena Corporation PLC
Run backtest to discover the historical profit from buying and selling
PRTA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Prothena Corporation PLC
Balance Sheet Decomposition
Prothena Corporation PLC
| Current Assets | 639.3m |
| Cash & Short-Term Investments | 618.8m |
| Receivables | 5.2m |
| Other Current Assets | 15.3m |
| Non-Current Assets | 57.1m |
| PP&E | 16m |
| Other Non-Current Assets | 41.1m |
| Current Liabilities | 56.9m |
| Accounts Payable | 25.4m |
| Accrued Liabilities | 29.1m |
| Other Current Liabilities | 2.4m |
| Non-Current Liabilities | 78.1m |
| Other Non-Current Liabilities | 78.1m |
Earnings Waterfall
Prothena Corporation PLC
|
Revenue
|
91.4m
USD
|
|
Operating Expenses
|
-282.4m
USD
|
|
Operating Income
|
-191m
USD
|
|
Other Expenses
|
44m
USD
|
|
Net Income
|
-147m
USD
|
Free Cash Flow Analysis
Prothena Corporation PLC
PRTA Profitability Score
Profitability Due Diligence
Prothena Corporation PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Prothena Corporation PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
PRTA Solvency Score
Solvency Due Diligence
Prothena Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Prothena Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRTA Price Targets Summary
Prothena Corporation PLC
According to Wall Street analysts, the average 1-year price target for
PRTA
is 68.1 USD
with a low forecast of 34.34 USD and a high forecast of 98.7 USD.
Ownership
PRTA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PRTA Price
Prothena Corporation PLC
| Average Annual Return | 82.94% |
| Standard Deviation of Annual Returns | 147.27% |
| Max Drawdown | -74% |
| Market Capitalization | 1.1B USD |
| Shares Outstanding | 53 720 500 |
| Percentage of Shares Shorted | 18.98% |
PRTA News
Last Important Events
Prothena Corporation PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Prothena Corporation PLC
Company Profile
Prothena Corporation PLC
Country
Industry
Market Cap
Dividend Yield
Description
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Contact
IPO
Employees
Officers
The intrinsic value of one
PRTA
stock under the Base Case scenario is
53.69
USD.
Compared to the current market price of 20.56 USD,
Prothena Corporation PLC
is
Undervalued by 62%.
You don't have any saved screeners yet
